NCT06158139View on ClinicalTrials.gov

Autologous CAR-T Cells Targeting B7-H3 in PDAC

PHASE1RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 18, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2028

Conditions
Pancreas CancerRelapseResistant Cancer
Interventions
BIOLOGICAL

iC9-CAR.B7-H3 T cell infusion

iC9-CAR.B7-H3 T cell product will be administered via intravenous injection over 5 - 10 minutes.

Trial Locations (1)

27599

RECRUITING

University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill

All Listed Sponsors
collaborator

M.D. Anderson Cancer Center

OTHER

lead

UNC Lineberger Comprehensive Cancer Center

OTHER